Neural O
Correlates O
of O
Auditory O
Verbal O
Hallucinations O
in O
Schizophrenia O
and O
the O
Therapeutic O
Response O
to O
Theta-Burst O
Transcranial O
Magnetic O
Stimulation O
Abstract O
Auditory O
verbal O
hallucinations O
( O
AVHs O
) O
are O
a O
core O
symptom O
of O
schizophrenia O
, O
and O
resistant O
to O
antipsychotic O
medication O
in O
a O
substantial O
proportion O
of O
patients O
. O

This O
study O
aimed O
to O
investigate O
the O
neural O
correlates O
of O
AVHs O
in O
schizophrenia O
patients O
and O
its O
response O
to O
a O
modified O
continuous O
theta-burst O
stimulation O
( O
cTBS O
) O
by O
transcranial O
magnetic O
stimulation O
. O

In O
a O
cross-sectional O
experiment O
, O
resting-state O
functional O
magnetic O
resonance O
images O
were O
collected O
from O
31 O
AVH O
schizophrenia O
patients O
, O
26 O
non-AVH O
schizophrenia O
patients O
, O
and O
33 O
sex-/age-matched O
healthy O
controls O
( O
HCs O
) O
. O

Functional O
connectivity O
strength O
( O
FCS O
) O
maps O
were O
compared O
among O
groups O
by O
1-way O
analysis O
of O
variance O
( O
ANOVA O
) O
. O

In O
a O
longitudinal O
experiment O
, O
16 O
and O
11 O
AVH O
patients O
received O
real O
and O
sham O
cTBS O
treatment O
for O
15 O
days O
, O
respectively O
. O

Notably O
, O
this O
was O
not O
a O
randomized O
control O
trail O
. O

Changes O
in O
AVH O
and O
FCS O
were O
analyzed O
by O
2-way O
ANOVA O
and O
2-sample O
t-test O
, O
respectively O
. O

In O
the O
cross-sectional O
experiment O
, O
comparison O
of O
FCS O
maps O
identified O
8 O
clusters O
among O
groups O
, O
but O
only O
one O
cluster O
( O
in O
left O
cerebellum O
) O
differed O
significantly O
in O
AVH O
patients O
compared O
to O
both O
HCs O
and O
non-AVH O
patients O
. O

In O
the O
longitudinal O
experiment O
, O
the O
real O
cTBS O
group O
showed O
a O
greater O
improvement O
in O
symptoms O
and O
a O
larger O
FCS O
decrease O
in O
left O
cerebellum O
than O
the O
sham O
group O
. O

Pearson O
’ O
s O
correlation O
analysis O
indicated O
that O
baseline O
FCS O
of O
the O
overlapping O
cerebellum O
cluster O
( O
between O
the O
cross-sectional O
and O
longitudinal O
findings O
) O
was O
negatively O
correlated O
with O
symptom O
improvement O
in O
the O
real O
treatment O
group O
. O

These O
findings O
emphasize O
the O
role O
of O
the O
left O
cerebellum O
in O
both O
the O
pathophysiology O
and O
clinical O
treatment O
of O
AVHs O
in O
schizophrenia O
patients O
. O

Materials O
and O
Methods O
This O
study O
is O
composed O
of O
cross-sectional O
and O
longitudinal O
experiments O
. O

All O
participants O
provided O
written O
informed O
consent O
before O
experiments O
. O

The O
cross-sectional O
experiment O
investigated O
the O
neural O
correlates O
of O
AVH O
by O
comparing O
FCS O
maps O
among O
AVH O
, O
non-AVH O
, O
and O
HC O
participants O
. O

The O
longitudinal O
experiment O
tested O
the O
clinical O
efficacy O
of O
a O
modified O
rTMS O
protocol O
and O
its O
underlying O
neural O
mechanism O
by O
rs-fMRI O
. O

Finally O
, O
a O
spatial O
overlap O
map O
was O
produced O
, O
utilizing O
the O
fMRI O
findings O
of O
both O
experiments O
, O
to O
evaluate O
the O
rTMS O
mechanism O
in O
terms O
of O
baseline O
abnormality O
( O
figure O
1 O
) O
. O

Notably O
, O
the O
longitudinal O
rTMS O
experiment O
was O
not O
a O
randomized O
control O
trail O
, O
although O
both O
real O
and O
sham O
treatment O
were O
performed O
in O
this O
part O
. O

Participants O
A O
total O
of O
57 O
patients O
diagnosed O
with O
refractory O
schizophrenia O
at O
the O
Anhui O
Mental O
Health O
Center O
( O
Hefei O
, O
China O
) O
were O
consecutively O
enrolled O
in O
this O
study O
( O
supplementary O
tables O
E1–E3 O
) O
. O

The O
study O
protocol O
was O
reviewed O
and O
approved O
by O
the O
Medical O
Ethics O
Committee O
of O
Anhui O
Medical O
University O
, O
Hefei O
, O
China O
. O

All O
participants O
satisfied O
the O
following O
inclusion O
criteria O
: O
( O
1 O
) O
diagnosis O
of O
schizophrenia O
using O
the O
Structured O
Clinical O
Interview O
for O
the O
Diagnostic O
and O
Statistical O
Manual O
of O
Mental O
Disorders O
, O
Fourth O
Edition O
( O
SCID-IV O
) O
, O
( O
2 O
) O
were O
taking O
stable O
doses O
of O
psychotropic O
medication O
for O
at O
least O
8 O
weeks O
before O
the O
study O
, O
and O
( O
3 O
) O
verbal O
intelligence O
quotient O
> O
85 O
as O
measured O
utilizing O
a O
Chinese O
version O
of O
the O
National O
Adult O
Reading O
Test O
. O

Exclusion O
criteria O
were O
as O
follows O
: O
( O
1 O
) O
history O
of O
significant O
head O
trauma O
or O
neurological O
disorders O
, O
( O
2 O
) O
alcohol O
or O
drug O
abuse O
, O
( O
3 O
) O
focal O
brain O
lesions O
on O
T1- O
or O
T2-weighted O
fluid-attenuated O
inversion-recovery O
magnetic O
resonance O
images O
, O
( O
4 O
) O
recent O
aggression O
or O
other O
forms O
of O
behavioral O
dysfunction O
, O
( O
5 O
) O
head O
motion O
exceeding O
3 O
mm O
in O
translation O
or O
3° O
in O
rotation O
during O
rs-fMRI O
scanning O
, O
or O
( O
6 O
) O
Hamilton O
Anxiety O
Rating O
Scale O
or O
Hamilton O
Depression O
Rating O
Scale O
score O
> O
7 O
. O

Patients O
were O
further O
classified O
into O
2 O
groups O
: O
those O
reporting O
AVHs O
of O
spoken O
speech O
at O
least O
5 O
times O
per O
day O
during O
the O
preceding O
8 O
weeks O
( O
AVH O
group O
, O
n O
= O
31 O
) O
and O
patients O
who O
had O
not O
experienced O
AVHs O
( O
or O
olfactory O
, O
gustatory O
, O
tactile O
hallucination O
) O
since O
the O
diagnosis O
of O
schizophrenia O
or O
within O
5 O
years O
before O
scans O
( O
non-AVH O
group O
, O
n O
= O
26 O
) O
. O

The O
most O
commonly O
positive O
syndromes O
of O
the O
non-AVH O
group O
were O
delusional O
disorder O
( O
n O
= O
15 O
) O
, O
impulsion O
( O
n O
= O
10 O
) O
, O
and O
restlessness O
( O
n O
= O
8 O
) O
. O

All O
AVH O
patients O
were O
refractory O
, O
which O
may O
be O
defined O
as O
the O
experience O
of O
persistent O
daily O
hallucinations O
without O
remission O
despite O
antipsychotic O
medication O
administered O
at O
an O
adequate O
dosage O
for O
at O
least O
12 O
weeks O
. O

With O
regard O
to O
AVH O
patients O
participating O
in O
the O
longitudinal O
rTMS O
study O
, O
additional O
exclusion O
criteria O
included O
( O
1 O
) O
age O
< O
18 O
years O
, O
( O
2 O
) O
non-removable O
metal O
objects O
in O
or O
around O
head O
, O
or O
( O
3 O
) O
prior O
history O
of O
seizure O
or O
history O
in O
first O
degree O
relatives O
. O

Finally O
, O
16 O
AVH O
patients O
provided O
their O
consent O
for O
real O
rTMS O
treatment O
. O

After O
the O
end O
of O
the O
rTMS O
treatment O
experiment O
, O
the O
researchers O
realized O
that O
a O
sham–control O
would O
be O
necessary O
to O
exclude O
the O
placebo O
effect O
of O
rTMS O
. O

According O
to O
the O
primary O
results O
of O
real O
stimulation O
( O
see O
Results O
) O
, O
a O
sample O
of O
7 O
participants O
proved O
large O
enough O
to O
identify O
the O
treatment O
effect O
( O
alpha O
= O
0.05 O
, O
beta O
= O
0.8 O
) O
. O

Fortunately O
, O
an O
interim O
inspection O
of O
another O
ongoing O
study O
( O
Randomized O
Clinical O
Trail O
[ O
RCT O
] O
number O
: O
NCT02863094 O
) O
allowed O
the O
researchers O
to O
collect O
data O
from O
11 O
refractory O
AVH O
patients O
( O
meeting O
the O
inclusion O
and O
exclusion O
criteria O
of O
this O
study O
) O
who O
had O
received O
sham O
rTMS O
. O

Thus O
, O
their O
data O
were O
utilized O
in O
the O
sham–control O
group O
in O
the O
current O
study O
. O

Thirty-three O
HCs O
with O
no O
history O
of O
neurological O
or O
psychiatric O
illnesses O
were O
randomly O
recruited O
from O
the O
local O
community O
. O

This O
group O
exhibited O
no O
gross O
abnormalities O
on O
brain O
MR O
images O
. O

MRI O
Data O
Acquisition O
Magnetic O
resonance O
images O
were O
acquired O
from O
2 O
scanners O
of O
the O
same O
type O
( O
3.0T O
, O
Discovery O
GE750w O
, O
General O
Electric O
) O
. O

One O
scanner O
was O
used O
for O
the O
sham O
treatment O
group O
, O
and O
the O
other O
for O
the O
real O
treatment O
group O
and O
cross-sectional O
experiment O
. O

Details O
were O
outlined O
in O
supplementary O
materials O
. O

Neuro-navigated O
rTMS O
The O
AVH O
patients O
made O
17 O
study-related O
visits O
to O
the O
hospital O
. O

On O
the O
first O
and O
last O
visits O
, O
the O
researchers O
acquired O
MRI O
data O
and O
assessed O
neuropsychological O
conditions O
and O
clinical O
symptoms O
. O

From O
the O
2nd O
to O
16th O
day O
, O
participants O
received O
3 O
daily O
sessions O
of O
cTBS O
treatment O
delivered O
using O
a O
MagStim O
Rapid O
stimulator O
( O
Magstim O
Company O
Ltd. O
) O
with O
a O
70-mm O
air-cooled O
figure-of-eight O
coil O
. O

One O
session O
of O
cTBS O
was O
40 O
seconds O
in O
duration O
and O
consisted O
of O
3-pulse O
bursts O
at O
50 O
Hz O
repeated O
every O
200 O
milliseconds O
( O
5 O
Hz O
) O
until O
a O
total O
of O
600 O
pulses O
was O
reached O
. O

To O
achieve O
cumulative O
aftereffects O
, O
this O
protocol O
was O
repeated O
3 O
times O
and O
( O
1800 O
pulses O
in O
total O
) O
separated O
by O
two O
15-minute O
breaks O
( O
controlled O
by O
a O
stopwatch O
) O
in O
line O
with O
previous O
methodological O
studies O
. O

The O
researchers O
delivered O
cTBS O
at O
80 O
% O
of O
the O
resting O
motor O
threshold O
( O
RMT O
) O
or O
the O
highest O
intensity O
the O
stimulator O
could O
deliver O
for O
this O
protocol O
( O
50 O
% O
of O
maximum O
output O
) O
. O

The O
RMT O
was O
determined O
at O
each O
visit O
according O
to O
a O
5-step O
procedure O
. O

The O
stimulation O
target O
, O
the O
left O
TPJ O
, O
was O
defined O
as O
a O
sphere O
of O
6-mm O
radius O
centered O
at O
Montreal O
Neurological O
Institute O
( O
MNI O
) O
coordinates O
[ O
−51 O
, O
−31 O
, O
23 O
] O
. O

This O
target O
was O
transformed O
into O
each O
participant O
’ O
s O
T1 O
space O
by O
applying O
an O
inverse O
matrix O
produced O
during O
T1 O
segmentation O
in O
SPM O
( O
www.fil.ion.ucl.ac.uk/spm O
) O
and O
TMStarget O
software O
. O

Then O
, O
each O
individual O
’ O
s O
target O
was O
imported O
into O
a O
frameless O
neuronavigation O
system O
( O
Visor O
2.0 O
, O
Advanced O
Neuro O
Technologies O
) O
. O

The O
coil O
was O
held O
tangentially O
to O
the O
skull O
pointing O
forward O
, O
with O
the O
center O
over O
the O
target O
sphere O
. O

Patients O
in O
the O
sham O
control O
group O
received O
the O
same O
rTMS O
protocol O
and O
treatment O
duration O
as O
the O
real O
rTMS O
group O
. O

The O
only O
difference O
was O
the O
usage O
of O
a O
sham O
coil O
( O
Magstim O
Company O
Ltd. O
) O
that O
produced O
a O
similar O
feeling O
on O
the O
participant O
’ O
s O
scalp O
as O
the O
real O
coil O
but O
did O
not O
induce O
a O
current O
in O
the O
cortex O
. O

Clinical O
Symptom O
and O
Neuropsychological O
Assessments O
Clinical O
symptoms O
of O
all O
patients O
were O
graded O
according O
to O
the O
Positive O
and O
Negative O
Syndrome O
Scale O
( O
PANSS O
) O
. O

In O
addition O
, O
all O
patients O
and O
HCs O
were O
evaluated O
using O
standardized O
neuropsychological O
tests O
( O
supplementary O
tables O
E1 O
and O
E2 O
) O
. O

For O
AVH O
patients O
participating O
in O
the O
rTMS O
study O
, O
the O
primary O
outcome O
was O
the O
Auditory O
Hallucination O
Rating O
Scale O
( O
AHRS O
) O
, O
which O
would O
be O
administered O
with O
other O
measures O
on O
the O
1st O
and O
17th O
visits O
. O

MRI O
Data O
Processing O
Functional O
image O
processing O
was O
carried O
out O
using O
the O
DPARSF O
( O
http O
: O
//rfmri.org O
) O
and O
SPM O
( O
www.fil.ion.ucl.ac.uk/spm O
) O
toolkits O
. O

The O
preprocessing O
included O
( O
1 O
) O
deleting O
the O
first O
5 O
volumes O
; O
( O
2 O
) O
slice O
timing O
and O
realignment O
; O
( O
3 O
) O
co-registering O
T1 O
to O
functional O
images O
; O
( O
4 O
) O
normalizing O
T1 O
to O
the O
MNI O
space O
and O
segmenting O
it O
into O
gray O
matter O
, O
white O
matter O
, O
and O
cerebrospinal O
fluid O
( O
spatial O
resolution O
: O
3 O
× O
3 O
× O
3 O
) O
; O
( O
5 O
) O
smoothing O
images O
with O
a O
4-mm O
isotropic O
Gaussian O
kernel O
; O
( O
6 O
) O
filtering O
temporal O
bandpass O
( O
0.01–0.1 O
Hz O
) O
, O
and O
regressing O
out O
15 O
nuisance O
signals O
( O
global O
mean O
, O
white O
matter O
, O
cerebrospinal O
fluid O
signals O
, O
and O
24 O
head-motion O
parameters O
. O

Subsequently O
, O
Pearson O
’ O
s O
correlations O
were O
conducted O
between O
the O
time O
series O
of O
all O
pairs O
of O
voxels O
to O
construct O
a O
whole-brain O
matrix O
for O
each O
participant O
. O

Finally O
, O
functional O
connectivity O
strength O
( O
FCS O
) O
defined O
as O
the O
sum O
of O
the O
coefficients O
between O
a O
given O
voxel O
and O
all O
other O
voxels O
, O
was O
then O
standardized O
by O
dividing O
by O
the O
average O
whole-brain O
FCS O
value O
. O

To O
eliminate O
voxels O
with O
weak O
correlations O
attributable O
to O
signal O
noise O
, O
the O
analysis O
was O
restricted O
to O
positive O
correlations O
( O
r O
> O
.25 O
, O
P O
< O
.001 O
) O
. O

Statistical O
Analysis O
For O
the O
cross-sectional O
study O
, O
demographic O
characteristics O
, O
neuropsychological O
scores O
, O
and O
imaging O
features O
were O
compared O
between O
the O
3 O
groups O
by O
one-way O
analysis O
of O
variance O
( O
ANOVA O
) O
. O

Notably O
, O
outliers O
in O
neuropsychological O
scores O
were O
identified O
before O
ANOVA O
by O
nonlinear O
regression O
analyses O
in O
GraphPad O
Prism O
. O

The O
Bonferroni O
or O
Tamhane O
’ O
s O
test O
was O
used O
for O
pair-wise O
post O
hoc O
comparisons O
. O

Clinical O
characteristics O
were O
compared O
between O
patient O
groups O
using O
2-sample O
t-tests O
. O

In O
the O
longitudinal O
study O
, O
the O
change O
in O
clinical O
symptom O
was O
analyzed O
by O
2-way O
( O
group O
by O
time O
) O
ANOVA O
. O

Since O
the O
MRI O
data O
of O
real O
and O
sham O
groups O
were O
acquired O
using O
different O
scanners O
, O
comparisons O
of O
pre- O
or O
post-treatment O
data O
between O
the O
groups O
largely O
reflect O
the O
systematic O
error O
of O
scanners O
rather O
than O
brain O
functional O
changes O
. O

However O
, O
the O
pre- O
to O
post-treatment O
alteration O
is O
comparable O
, O
since O
the O
scanner O
effect O
could O
be O
well O
controlled O
by O
the O
within O
center O
subtraction O
( O
post- O
minus O
pre-state O
) O
. O

Thus O
, O
the O
FCS O
changes O
following O
treatment O
were O
compared O
between O
groups O
by O
2-sample O
t-test O
. O

All O
voxel-based O
imaging O
analyses O
were O
corrected O
by O
Gaussian O
Random O
Field O
( O
GRF O
) O
theory O
( O
cluster-defined O
threshold O
, O
P O
< O
.05 O
, O
cluster-level O
corrected O
P O
< O
.05 O
) O
. O

Complementary O
Experiments O
First O
, O
target-to-whole O
brain O
functional O
connectivity O
was O
used O
as O
a O
secondary O
measure O
. O

Second O
, O
longitudinal O
data O
of O
2 O
HC O
groups O
from O
2 O
scanning O
sites O
were O
utilized O
to O
clarify O
whether O
the O
MRI O
findings O
for O
the O
TMS O
effect O
were O
influenced O
by O
scanner O
. O

Third O
, O
we O
re-computed O
the O
FCS O
for O
correlations O
> O
0 O
to O
test O
the O
robustness O
of O
the O
findings O
. O

Fourth O
, O
all O
image-based O
statistical O
analyses O
were O
corrected O
for O
multiple O
comparisons O
using O
Threshold-Free O
Cluster O
Enhancement O
in O
FSL O
software O
( O
corrected O
P O
< O
.05 O
) O
. O

See O
details O
of O
these O
experiments O
in O
supplementary O
materials O
. O

